- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04817709
Development of a Patient Decision Aid for Women Considering Breast Reconstruction
Development of a Patient Decision Aid for Women Considering Breast Reconstruction: User-Centered Design and Field-Testing
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVES:
I. To design a patient decision aid video about breast reconstruction. II. To pilot test its acceptability with women. III. To field test the feasibility of delivery pre-consultation and efficacy at preparing women for their discussion with their plastic surgeon.
OUTLINE:
FOCUS GROUP: Survivors who previously considered breast reconstruction participate in a 40 to 60-minute focus group to gather feedback on currently-available patient decision aids and educational materials. The research team uses their feedback to create an initial prototype of a patient decision aid video
PILOT TEST: Survivors who previously considered breast reconstruction review the initial prototype of the patient decision aid video, then complete a questionnaire providing their feedback about the video's strengths and areas that could be improved. The research team then incorporates their feedback into the video."
FIELD TEST: Patients are randomized to 1 of 2 arms.
ARM I: Before their appointment, patients spend up to 30 minutes viewing a video and workbook. They also spend 5 to 10 minutes completing a questionnaire before and after the video and workbook, and again after their appointment. After their appointment, the research assistant reviews their medical record to confirm what decisions the patient and doctor made about breast reconstruction.
ARM II: During their appointment, patients spend up to 30 minutes reviewing the standard educational booklet about breast reconstruction. They also spend 5 to 10 minutes completing a questionnaire before and after the booklet, and again after their appointment. After their appointment, the research assistant reviews their medical record to confirm what decisions the patient and doctor made about breast reconstruction.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Aims 1 and 2: Patients who are 6 months to 3 years post-mastectomy surgery
- Aim 3: Patients who are scheduled for their first breast reconstruction consultation with plastic surgery
- Able to speak, read, and write English
Exclusion Criteria:
- Women with cognitive or psychological impairment (e.g., depression, anxiety, severe mental illness; as documented in their medical record)
- Women for whom the video and workbook would not be appropriate due to clinical characteristics or contraindications (as determined by a provider)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Arm 1
Patients view a video and read a workbook over 30 minutes about breast reconstruction surgery before their appointment.
Patients also complete a questionnaire over 5-10 minutes before and after the video and after talking with the plastic surgeon.
Patients' medical records are reviewed once they have made a decision about the type of reconstruction (if any).
|
Review of medical records
Other Names:
Complete questionnaires
Review workbook
Other Names:
Watch video
|
|
Arm 2
Patents receive an educational booklet about breast reconstruction surgery during appointment.
Patients also complete a questionnaire over 5-10 minutes before and after talking with the plastic surgeon.
Patients' medical records are reviewed once they have made a decision about the type of reconstruction (if any).
|
Review of medical records
Other Names:
Complete questionnaires
Receive educational materials
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Delivery Rate
Time Frame: Up to 3 months prior to plastic surgery consultation
|
The statistician will calculate how many women to whom the research assistant was able to deliver the video/workbook or educational materials (i.e., by sending them the URL link or scheduling time to show them the video/workbook or educational materials on an iPad at the clinic), out of the total n = 130 eligible women.
The statistician will also calculate the rates of women who prefer to view the video and workbook at home or at the clinic; and of women who re-visit the video and workbook after the consultation.
|
Up to 3 months prior to plastic surgery consultation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Breast Reconstruction Knowledge Questionnaire
Time Frame: Up to 3 months prior to plastic surgery consultation
|
This questionnaire includes 10 true/false items assessing participants' knowledge of breast reconstruction.
Items are scored such that 0% correct responses equals no knowledge and 100% correct responses equals perfect knowledge.
|
Up to 3 months prior to plastic surgery consultation
|
|
Preparation for Decision Making Scale
Time Frame: Immediately after intervention
|
This questionnaire includes 11 multiple choice items assessing how well-prepared participants feel they are for making this shared medical decision with their doctors.
Participants rate each item on 5-point Likert scale from 1 (Not at all) to 5 (a great deal).
To calculate a total score, responses are summed and multiplied by 2 to yield the total score.
Total scores range from 0 (Poorly prepared) to 100 (Excellently prepared).
Alpha coefficients observed between 0.92 to 0.96.
This scale discriminates between people who do/do not find the decision aid helpful (p < 0.0001).
For this study, a threshold of 75 out of 100 will be considered acceptable.
|
Immediately after intervention
|
|
Decisional Conflict Scale
Time Frame: Immediately before intervention, immediately after intervention, immediately after consultation
|
This scale includes 16 question-items assessing participants' level of decisional conflict, defined as anxiety that blocks taking action.
Participants rate each item on a Likert Scale with 5 responses from 0 (Not at All) to 4 (Extremely).
Scores are summed, divided by 16, and multiplied by 25 to yield a total score of 0 (Less conflicted) to 100 (Highly conflicted).
Total scores above 37.5 out of 100 are associated with delaying decisions and uncertainty about implementing their preferred treatment option; scores below 25 out of 100 are associated with making decisions and successfully implementing their preferred treatment option.
|
Immediately before intervention, immediately after intervention, immediately after consultation
|
|
BREAST-Questionnaire (Q)
Time Frame: Up to 1 year prior to surgery, up to 1 year after surgery
|
The BREAST-Q assesses women's self-reported ratings of their satisfaction with their breasts and associated quality of life in terms of psychosocial, sexual, and physical well-being.
Participants rate 64 items from 1 (Very Dissatisfied) to 4 (Very Satisfied).
Psychometric properties include a person separation index of 0.76 to 0.95, Cronbach's alphas of 0.81 to 0.96, and test-retest reproducibility of 0.73 to 0.96 Before surgery, after surgery
|
Up to 1 year prior to surgery, up to 1 year after surgery
|
|
Type of surgery completed
Time Frame: Up to 1 year after surgery
|
The study coordinator will abstract the type(s) of reconstructive surgery completed, including immediate versus delayed reconstruction, autologous versus implant-based reconstruction, nipple reconstruction, contralateral balancing surgery, oncoplastic tissue rearrangement, and/or no reconstruction.
This questionnaire is not a validated scale and thus no scoring or psychometric properties are appropriate.
Responses will be used to model potential covariate relationships with the primary and other secondary outcome measures.
|
Up to 1 year after surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gregory Reece, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PA17-0002 (Other Identifier: M D Anderson Cancer Center)
- NCI-2020-07838 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Carcinoma
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingEstrogen Receptor Positive | Ductal Breast Carcinoma In Situ | Grade 1 Invasive Breast Carcinoma | Grade 2 Invasive Breast Carcinoma | Grade 3 Invasive Breast Carcinoma | Invasive Ductal and Lobular Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast CarcinomaUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage IA Breast Cancer | Stage IB Breast Cancer | Recurrent Breast Cancer | Ductal Breast Carcinoma in Situ | Invasive Lobular Breast Carcinoma | Lobular Breast Carcinoma in Situ | Invasive Ductal Breast CarcinomaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); Canadian Cancer Trials GroupActive, not recruitingStage II Breast Cancer | Stage IIIA Breast Cancer | Invasive Breast Carcinoma | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Lobular Breast Carcinoma | Ductal Breast Carcinoma | Tubular Breast Carcinoma | Medullary Breast CarcinomaUnited States, Canada
-
University of Texas at AustinWashington University School of Medicine; Ohio State UniversityCompletedStage I Breast Cancer | Stage II Breast Cancer | Breast Cancer Female | Ductal Carcinoma in Situ | Lobular Breast Carcinoma | Stage III Breast Cancer | Ductal Breast CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Breast Carcinoma | Triple-Negative Breast Carcinoma | HER2-Negative Breast Carcinoma | Bilateral Breast Carcinoma | Localized Breast CarcinomaUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)CompletedStage 0 Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Lobular Breast Carcinoma In Situ | Ductal Breast Carcinoma In Situ | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedInvasive Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | Lobular Breast Carcinoma | Postmenopausal | Ductal Breast Carcinoma | Ductal Breast Carcinoma In SituUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyCompletedInflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Invasive Lobular Breast Carcinoma | Invasive Ductal Breast Carcinoma | Mucinous Ductal Breast Carcinoma | Papillary Ductal Breast Carcinoma | Tubular Ductal Breast CarcinomaUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage 0 Breast Cancer AJCC v8 | Prognostic Stage 0 Breast Cancer AJCC v8 | Breast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | Multicentric Breast Carcinoma | Bilateral Breast CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedBreast Cancer | Ductal Breast Carcinoma in Situ | Atypical Ductal Breast Hyperplasia | Lobular Breast Carcinoma in SituUnited States
Clinical Trials on Medical Chart Review
-
M.D. Anderson Cancer CenterTerminatedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMalignant Central Nervous System Neoplasm | Malignant Skull Base NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLCCompletedIncidence and Prevalence of Cancer in People Living With HIV/AIDS at Cancer Centers in Latin AmericaHIV Infection | Malignant Neoplasm | Recurrent Malignant Neoplasm | Human Immunodeficiency Virus 1 PositiveMexico, Argentina, Brazil
-
M.D. Anderson Cancer CenterRecruitingCutaneous MelanomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHead and Neck CarcinomaUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Sarcoma | Recurrent Uterine Corpus Carcinoma | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer | Recurrent Cervical Carcinoma | Stage III Uterine Sarcoma | Stage IV Uterine Sarcoma | Stage I Uterine... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedMalignant Neoplasm | Malignant Respiratory Tract Neoplasm | Malignant Thoracic NeoplasmUnited States, Cyprus
-
M.D. Anderson Cancer CenterNational Institute of Allergy and Infectious Diseases (NIAID)RecruitingEvaluating Clonogenic Epithelial Cell Populations in Patients With Bronchiolitis Obliterans SyndromeBronchiolitis ObliteransUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)Completed